Director Floyd F. Petersen of Amgen Pharmaceuticals Sells 500 Shares, Stock Price Drops 1.7%

Summary

Floyd F. Petersen, a director of Amphastar Pharmaceuticals, sold 500 shares at an average price of $28.38, totaling $14,190. His holdings decreased by 0.67%, now amounting to 73,909 shares valued at approximately $2.1 million. Following the sale, the stock price dropped by 1.7% to $27.80, with a market cap of $1.32 billion. Analyst Piper Sandler lowered the target price from $36 to $32, maintaining a ‘neutral’ rating. Institutional investors hold 65.09% of the company’s shares, which focuses on generic drugs and proprietary injectable products.Market Beat

Impact Analysis

The event is at the company level, as it directly relates to Amphastar Pharmaceuticals and involves insider trading activity. The sale of shares by Floyd F. Petersen might signal potential concerns or changes in the board member’s perception of the company’s short-term prospects. The stock’s 1.7% drop could reflect market sensitivity to insider actions, possibly exacerbated by Piper Sandler’s downgrade of the target price. The high level of institutional ownership (65.09%) suggests that such insider activities are closely monitored and could influence investor sentiment.Market Beat Opportunities may arise for investors to purchase shares at a lower price if they believe the company maintains strong fundamentals in its focus areas of generic drugs and injectable products. Risks include potential further declines in stock price if additional insider sales or unfavorable analyst reports occur.